Topic: Prostate Cancer

Transperineal Prostate Biopsy: State of the Art

Roberto Miano, MD, compares transperineal versus transrectal access for prostate biopsies. He argues that transperineal is safer in terms of infectious complications and more accurate for detecting cancer versus a transrectal approach. Therefore, it is essential that clinicians receive proper training for the procedure.

Read More

The LUGPA Alternative Payment Model (APM) on Newly Diagnosed PCa and the Role of Active Surveillance

R. Jonathan Henderson, MD, summarizes the Large Urology Group Practice Association’s (LUGPA’s) efforts to develop an alternative payment model (APM) for urologists treating newly diagnosed prostate cancer patients. He explains the roadblocks to reaching this goal, including conflicts with the Physician-Focused Payment Model Technical Advisory Committee (PTAC).

Read More

M0 Space and The SPARTAN Trial

Matthew E. Nielsen, MD, MS, discusses the challenge asymptomatic microscopic hematuria (AMH) poses in our urologic practices. He summarizes the evolution of guidelines for evaluating hematuria and trade-offs in benefit, harm, and cost of different diagnostic approaches.

Read More

Advanced Disease — A Real Need for Understanding and Shared Care

Daniel P. Petrylak, MD, stresses the importance of taking a multidisciplinary approach when treating prostate cancer. Not only does this mean involving urologists, oncologists, and primary care physicians for better access to therapies and coordination of care, but also involving nutritionist, mental health professionals, and pain management experts for maintaining patients’ quality of life.

Read More

Integrating the AUA Guidelines into Your Practice

Michael S. Cookson, MD, MMHC, describes how urologists can use American Urological Association (AUA) guidelines to better manage metastatic castration resistant prostate cancer (mCRPC) patients. He stresses the importance of urologists serving as the primary caregiver, the multidisciplinary care model, and organized sequencing of treatments and therapeutics.

Read More

Join the GRU Community

- Why Join? -